Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASKG315 + pembrolizumab
- Development stage
- Phase 1
- Lead developer
- AskGene Pharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ASKG315 + pembrolizumab is a combination regimen under clinical investigation for the treatment of advanced solid tumors. ASKG315 is a novel engineered cytokine prodrug, specifically an interleukin-15 (IL-15) prodrug designed for proteolytic activation and targeted immune stimulation, developed using AskGene Pharma’s SmartKine® cytokine prodrug technology. Its mechanism extends the half-life of IL-15 and improves safety by restricting activation to the tumor microenvironment, stimulating natural killer (NK) cells and CD8+ T cells for anti-tumor activity. Pembrolizumab is a monoclonal antibody that blocks programmed cell death protein 1 (PD-1), thereby enhancing T-cell–mediated immune response against tumors. The combination aims to synergistically augment antitumor immunity through checkpoint inhibition and cytokine-mediated immune cell activation.
- Other names
- ASKG-315ASKG315ASKG 315ASKG215βIL-15 Fc fusion prodrugIL15 Fc fusion prodrugIL 15 Fc fusion prodrugprogrammed cell death protein 1 antibody
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on ASKG315 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASKG315 + pembrolizumab.